ArticleMalaria journal2026
Development of novel Aotus nancymaae non-human primate model for the evaluation of Plasmodium vivax blood stage vaccines and immunoprophylactics.
Article in Malaria journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundFew well-established in vivo animal models reflect the complexity of human malaria infection and immunity, and even fewer have been predictive of the potential of malaria vaccines or prophylactic therapies. Here, we characterized and optimized an Aotus nancymaae non-human primate (NHP) model of Plasmodium vivax (Pv) blood stage infection to enable the testing of novel vaccines and immunoprophylactics.
methodsUsing direct blood stage infection, we selected Vietnam-IV as the most virulent P. vivax strain from seven monkey adapted strains. We next determined the infectious dose with the lowest variability at doses of 0.3 (n = 3), 1.0 (n = 6) and 2.5 (n = 3) × 10^6 infected red blood cells (iRBC) in spleen-intact A. nancymaae non-human primates (NHPs). In addition, complete blood count (CBC) was measured during blood stage infection. Genomic sequencing was performed for P. vivax Vietnam-IV candidate Duffy Binding Protein-II. Finally, we evaluated the efficacy of a monoclonal antibody (mAb 099100) against DBP-II to protect against blood infection challenge.
resultsThe P. vivax Vietnam-IV monkey adapted strain at dose of 2.5 × 10^6 gave infection kinetics with the lowest coefficient variation (15-23%). CBC results at a low (0.3 × 10^6) and high (2.5 × 10^6) dose showed a significant increase in lymphocytes (5.0-5.3 to 7.0-8.5 10^9/l) and a decrease of neutrophils (1.9-3.0 to 0.6-1.2) and platelets (413-458 to 23-68 10^9/l) during acute infection. In a pilot study testing the anti-DBPII mAb 099100, we observed that 1 of 3 monkeys was partially protected against P. vivax as measured by need for treatment intervention (compared with 0 out of 3 monkeys in the control group). P. vivax Vietnam-IV genomic data showed that line was a single clone with a single gene copy of blood stage PvDBPII with single nucleotide polymorphisms outside mAb binding sites.
conclusionsOur study showed a P. vivax blood stage A. nancymaae model with well-characterized clinical, hematological and serological parameters during the course of infection. The challenge appeared stringent and suggests a high titer or high potency of mAb is needed for protection. This model can set the foundation for the evaluation of emerging P. vivax blood stage vaccines, monoclonal antibodies, anti-malarial drugs and prophylactics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.